查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球神经内分泌肿瘤治疗市场 - 2023-2030
市场调查报告书
商品编码
1279680

全球神经内分泌肿瘤治疗市场 - 2023-2030

Global Neuroendocrine Tumor Treatment Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球神经内分泌肿瘤治疗市场预计将出现有利可图的增长，到 2022 年将达到 50.532 亿美元，到 2030 年将达到 103.987 亿美元。 神经内分泌肿瘤治疗市场预计在预测期内（2023-2030 年）的复合年增长率为 9.7%。 主要市场参与者正在寻求各种战略，包括併购、产品批准和协议，以扩大产品范围和加强产品组合，以进入神经内分泌肿瘤治疗市场，扩大业务范围，提高竞争力。

例如，2022 年 9 月 21 日，礼来公司宣布，美国食品和药物管理局 (FDA) 确定 RET（在宣布批准 Rethmo（Selpercatinum，40 毫克和 80 毫克胶囊）期间重新排列）用于成人患者局部晚期或转移性实体瘤转染）基因融合。 该适应症根据 ORR 和反应持续时间 (DOR) 获得加速批准。 对该适应症的持续批准可能取决于验证性研究中临床效用的验证和描述。

神经内分泌肿瘤病例数量的增加、产品批准的增加、研究的增加以及意识的提高是推动全球神经内分泌肿瘤治疗市场增长的因素。

市场动态

越来越多的临床研究正在推动全球神经内分泌肿瘤治疗市场的增长。

越来越多的旨在治疗神经内分泌肿瘤的临床研究正在推动全球神经内分泌肿瘤治疗市场的增长。 例如，2022 年 9 月，美国国家癌症研究所宣布在 NIH 临床中心进行一项新的 I/II 期临床试验，以针对无法手术或转移性神经内分泌肿瘤。两种被认为以相似方式起作用的药物的混合物的疗效被评估。 一种药物 lutathera 会照射身体以诱导 DNA 损伤，而第二种药物 PARP 抑製剂奥拉帕尼会阻止 DNA 损伤的修復。

政府的努力和增加的资金为全球神经内分泌肿瘤治疗市场提供了增长机会

不断增加的政府资金和举措为未来几年全球神经内分泌肿瘤治疗市场带来了充满希望的增长机会。 例如，2022 年 1 月，澳大利亚联邦卫生部针对 2021 年罕见癌症、罕见疾病和未满足需求 (RCRDUN) 的资金展望，宣布了 6340 万美元用于研究罕见疾病和罕见癌症的资金，并提供了美元赠款。

COVID-19 影响分析

COVID-19 分析包括 COVID 之前、COVID 和 COVID 之后的情景、价格动态（与 COVID 之前的情景相比，大流行期间和之后的价格变化）、供需范围（贸易导致的需求和供应变化）限制、封锁和后续问题）；我打算解释製造商为此做了什么。

俄乌衝突分析

2022年2月24日，俄罗斯联邦入侵乌克兰，在居民中造成极大混乱，1200万人背井离乡寻求庇护。 超过 700 万人逃往乌克兰的其他地区，500 万人逃往边境国家。 这阻碍了该地区的市场增长，并对全球市场增长产生负面影响。

全球经济衰退影响分析

医疗保健行业并非完全不受经济衰退的影响，即使在过去的金融危机期间，医疗机构也在考虑裁员和招聘。 但由于其固有的性质，它比其他部门处理得更好。 然而，随着通胀继续上升，经济衰退危机威胁着市场。 经济衰退将继续的紧张局势正在加剧。

人工智能影响分析

在癌症诊断、药物发现和肿瘤精准医学中采用人工智能和机器学习来提高治疗标准和患者体验，将在预测期内推动全球神经内分泌肿瘤治疗市场产生积极影响

内容

第一章调查方法及范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按处理分类的片段
  • 按指示摘录
  • 按给药途径分类的片段
  • 最终用户

第四章市场动态

  • 影响因素
    • 司机
      • 神经内分泌肿瘤病例数增加
      • 产品批准
      • 启动研究活动
    • 约束因素
      • 治疗的副作用
    • 机会
    • 政府举措
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 监管分析
  • 价格分析
  • 专利分析
  • 害虫分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格和动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌衝突分析

第八章全球经济衰退分析

第9章人工智能的影响分析

第 10 章按药物类型分类

  • 生长抑素类似物 (SSA)
  • 靶向药物
  • 其他

第11章适应症

  • 消化系统
  • 肺
  • 胰腺
  • 其他

第12章给药途径

  • 口语
  • 注射

第 13 章最终用户

  • 医院
  • 癌症研究中心
  • 门诊手术中心

第14章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第15章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十六章公司简介

  • 辉瑞公司
    • 公司简介
    • 治疗类型组合和说明
    • 财务摘要
    • 主要发展状况
  • Ipsen Pharmaceuticals
  • Novartis
  • AVEO Pharmaceuticals, Inc.
  • Eli Lilly & Company
  • CK Hutchison Holdings（HUTCHMED）
  • C.H. Boehringer Sohn Ag & Co. KG（Boehringer Ingelheim International GmbH）
  • Lantheus Holdings, Inc.
  • Merck & Co., Inc.
  • Sanofi

第17章 附录

简介目录
Product Code: PH2122

Market Overview

The global neuroendocrine tumor treatment market reached USD 5,053.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 10,398.7 million by 2030. The neuroendocrine tumor treatment market is expected to exhibit a CAGR of 9.7% during the forecast period (2023-2030). The key market players are adopting various strategies such as mergers and acquisitions, product approvals, and agreements to increase product reach and strengthen their product portfolios, in order to enter or expand their business offerings and competitiveness in the neuroendocrine tumor treatment market.

For instance, on September 21, 2022, Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) approved Retevmo (selpercatinib, 40 mg & 80 mg capsules) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection (RET) gene fusion that has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on ORR and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.

The growing cases of neuroendocrine tumors, increasing product approvals, growing research, and increasing awareness are the factors driving global neuroendocrine tumor treatment market growth.

Market Dynamics

The Increasing Number of Clinical Research is Driving the Global Neuroendocrine Tumor Treatment Market Growth.

The growing number of clinical research for the treatment of neuroendocrine tumors is driving the global neuroendocrine tumor treatment market growth. For instance, according to a new published by National Cancer Institute in September 2022, a phase I/II clinical trial at the NIH Clinical Center assesses the efficacy of a mixture of two medications that may function in complementary manners to target inoperable or metastatic neuroendocrine tumors. One agent, lutathera, radiates radiation inside the body, inducing DNA damage, and the second agent, olaparib, a PARP inhibitor, stops the restoration of DNA breaks.

The Increasing Government Initiatives and Funding Provide Growth Opportunities to the Global Neuroendocrine Tumor Treatment Market

The increasing government funding and initiatives are presenting the global neuroendocrine tumor treatment market with prospective growth opportunities in the upcoming years. For instance, in January 2022, the Department of Health of the Commonwealth of Australia provided a grant of USD 63.4 million for the rare diseases and rare cancers investigation in response to the 2021 Rare Cancers, Rare Diseases and Unmet Need (RCRDUN) funding prospect.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

The Russian Federation's invasion of Ukraine on February 24, 2022, generated a huge dislocation of the residents with an assessed 12 million individuals escaping their residences and scouring for protection. Over seven million individuals were internally replaced to additional regions of Ukraine, while five million fled to bordering nations. This has disturbed the market growth in this region thereby negatively impacting the global market growth.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession.

Artificial Intelligence Impact Analysis

The employment of artificial intelligence and machine learning in cancer diagnosis, drug development, and precision medicine in oncology to improve the treatment standard and patient experiences are positively impacting the global neuroendocrine tumor treatment market in the forecast period.

Segment Analysis

The global neuroendocrine tumor treatment market is segmented based on therapy type, indication, route of administration, end-user, and region.

The Pancreatic Neuroendocrine Tumor segment is Estimated to Hold a 20% Share of the Global Market by 2030.

Owing to the increasing research in the pancreatic neuroendocrine tumor, the segment is estimated to hold around 20% of the total neuroendocrine tumor treatment market by 2030. For instance, according to a news article published by Northwestern University, a blend therapy practice employing two chemotherapy medications enhanced therapy reaction and progression-free survival in individuals with advanced pancreatic neuroendocrine tumors.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Global Neuroendocrine Tumor Treatment Market Share During the Forecast Period.

Europe is estimated to hold around 28.7% of the total neuroendocrine tumor treatment market owing to the market developments in this region. For instance, in April 2021, Germany's ITM, or Isotopen Technologien Munchen a privately held biotechnology and radiopharmaceutical group of corporations, secured a $109 million round of loan financing to advance its precision oncology pipeline and fund late-stage development for its neuroendocrine cancer program.

Competitive Landscape

The major global players in the market include: Pfizer, Inc., Ipsen Pharmaceuticals, Novartis, AVEO Pharmaceuticals, Inc., Eli Lilly & Company, CK Hutchison Holdings (HUTCHMED), C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH), Lantheus Holdings, Inc., Merck & Co., Inc. and Sanofi among others.

Why Purchase the Report?

  • To visualize the global neuroendocrine tumor treatment market segmentation based on therapy type, indication, route of administration, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of neuroendocrine tumor treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global neuroendocrine tumor treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by End User

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Cases of Neuroendocrine Tumors.
      • 4.1.1.2. Product Approvals.
      • 4.1.1.3. Increase in Research Activities.
    • 4.1.2. Restraints
      • 4.1.2.1. Treatment Side Effects.
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. PEST Analysis
  • 5.6. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Therapy Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 10.1.2. Market Attractiveness Index, By Therapy Type
  • 10.2. Somatostatin analogs (SSAs)
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Targeted therapy
  • 10.4. Others

11. By Indication

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Gastrointestinal*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Lungs
  • 11.4. Pancreas
  • 11.5. Others

12. By Route of Administration

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.1.2. Market Attractiveness Index, By Route of Administration
  • 12.2. Oral
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Injectable

13. By End User

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 13.1.2. Market Attractiveness Index, By End User
  • 13.2. Hospitals
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Cancer Research Center
  • 13.4. Ambulatory Surgery Centers

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Pfizer, Inc.
    • 16.1.1. Company Overview
    • 16.1.2. Therapy Type Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. Ipsen Pharmaceuticals
  • 16.3. Novartis
  • 16.4. AVEO Pharmaceuticals, Inc.
  • 16.5. Eli Lilly & Company
  • 16.6. CK Hutchison Holdings (HUTCHMED)
  • 16.7. C.H. Boehringer Sohn Ag & Co. KG (Boehringer Ingelheim International GmbH)
  • 16.8. Lantheus Holdings, Inc.
  • 16.9. Merck & Co., Inc.
  • 16.10. Sanofi

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us